250 related articles for article (PubMed ID: 35357651)
1. Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review.
Marshall GS; Fergie J; Presa J; Peyrani P
Infect Dis Ther; 2022 Jun; 11(3):937-951. PubMed ID: 35357651
[TBL] [Abstract][Full Text] [Related]
2. Potential public health impact of a
Huang L; Snedecor SJ; Balmer P; Srivastava A
Postgrad Med; 2022 May; 134(4):341-348. PubMed ID: 33615973
[TBL] [Abstract][Full Text] [Related]
3. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults.
Beran J; Dražan D; Enweonye I; Bhusal C; Toneatto D
mSphere; 2021 Dec; 6(6):e0055321. PubMed ID: 34787449
[TBL] [Abstract][Full Text] [Related]
5. Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
Collins JP; Crowe SJ; Ortega-Sanchez IR; Bahta L; Campos-Outcalt D; Loehr J; Morgan RL; Poehling KA; McNamara LA
MMWR Morb Mortal Wkly Rep; 2024 Apr; 73(15):345-350. PubMed ID: 38635488
[TBL] [Abstract][Full Text] [Related]
6. A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.
Ruiz Garcia Y; Abitbol V; Pellegrini M; Bekkat-Berkani R; Soumahoro L
Infect Dis Ther; 2022 Apr; 11(2):639-655. PubMed ID: 34591258
[TBL] [Abstract][Full Text] [Related]
7. The impact of regional disparities on the availability of meningococcal vaccines in the US.
Schley K; Jodar E; Presa JV; Willis SJ; Prener CG
BMC Public Health; 2024 Jul; 24(1):1771. PubMed ID: 38961431
[TBL] [Abstract][Full Text] [Related]
8. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
Burman C; Alderfer J; Snow VT
J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
[TBL] [Abstract][Full Text] [Related]
9. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB.
Bekkat-Berkani R; Fragapane E; Preiss S; Rappuoli R; Sohn WY; Soumahoro L; Vadivelu K
J Infect; 2022 Nov; 85(5):481-491. PubMed ID: 36087745
[TBL] [Abstract][Full Text] [Related]
10. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I
Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256
[TBL] [Abstract][Full Text] [Related]
11. Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study.
Szenborn L; Block SL; Jackowska T; Konior R; D'Agostino D; Smolenov I; Toneatto D; Welsch JA
Pediatr Infect Dis J; 2018 May; 37(5):475-482. PubMed ID: 29329168
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.
Saez-Llorens X; Aguilera Vaca DC; Abarca K; Maho E; Graña MG; Heijnen E; Smolenov I; Dull PM
Hum Vaccin Immunother; 2015; 11(6):1507-17. PubMed ID: 25969894
[TBL] [Abstract][Full Text] [Related]
13. Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France.
de Pouvourville G; Breau-Brunel M; Loncle-Provot V; Beck E; Gaugain L; Nachbaur G; Pribil C
Pharmacoecon Open; 2024 May; ():. PubMed ID: 38780884
[TBL] [Abstract][Full Text] [Related]
14. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
[TBL] [Abstract][Full Text] [Related]
15. Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults.
Sáez-Llorens X; Beltran-Rodriguez J; Novoa Pizarro JM; Mensi I; Keshavan P; Toneatto D
Hum Vaccin Immunother; 2018 May; 14(5):1161-1174. PubMed ID: 29601256
[TBL] [Abstract][Full Text] [Related]
16. Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults.
Beeslaar J; Absalon J; Balmer P; Srivastava A; Maansson R; York LJ; Perez JL
Vaccine; 2018 Jun; 36(28):4004-4013. PubMed ID: 29861182
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
Gandhi A; Balmer P; York LJ
Postgrad Med; 2016 Aug; 128(6):548-56. PubMed ID: 27467048
[TBL] [Abstract][Full Text] [Related]
18. Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II study.
Welsch JA; Senders S; Essink B; Klein T; Smolenov I; Pedotti P; Barbi S; Verma B; Toneatto D
Vaccine; 2018 Aug; 36(35):5309-5317. PubMed ID: 30061029
[TBL] [Abstract][Full Text] [Related]
19. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
[TBL] [Abstract][Full Text] [Related]
20. Disparities in healthcare providers' interpretations and implementations of ACIP's meningococcal vaccine recommendations.
Huang L; Goren A; Lee LK; Li VW; Dempsey A; Srivastava A
Hum Vaccin Immunother; 2020 Apr; 16(4):933-944. PubMed ID: 31634035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]